Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia.
Sign Up to like & getrecommendations! Published in 2021 at "Atherosclerosis"
DOI: 10.1016/j.atherosclerosis.2021.11.032
Abstract: BACKGROUND AND AIMS Familial combined hyperlipidemia (FCHL) is one of the most common inherited lipid phenotypes, characterized by elevated plasma concentrations of apolipoprotein B-100 and triglycerides. The genetic inheritance of FCHL remains poorly understood. The… read more here.
Keywords: risk; cardiovascular risk; familial combined; fchl ... See more keywords
ANGPTL3 gene variants in subjects with familial combined hyperlipidemia
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-86384-y
Abstract: Angiopoietin-like 3 (ANGPTL3) plays an important role in lipid metabolism in humans. Loss-of-function variants in ANGPTL3 cause a monogenic disease named familial combined hypolipidemia. However, the potential contribution of ANGPTL3 gene in subjects with familial… read more here.
Keywords: subjects familial; angptl3 gene; familial combined; gene ... See more keywords
Usage of a new pharmacological agent of ultra-small phospholipid nanoparticles (micelles) in the treatment of combined hyperlipidemia
Sign Up to like & getrecommendations! Published in 2020 at "European Heart Journal"
DOI: 10.1093/ehjci/ehaa946.3007
Abstract: Based on the developed technology of prerparation of ultra small size phospholipid nanoparticles without the use of detergents/surfactants and stabilizers drug preparation, exhibiting hypolipidemic properties has been obtained. Preclinical studies have shown that phospholipid nanoparticles… read more here.
Keywords: cholesterol; study; phospholipid nanoparticles; treatment combined ... See more keywords